U.S. Markets open in 6 hrs 9 mins
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    44,033.57
    +1,740.70 (+4.12%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • In December 2019, Kodiak Sciences Inc (NASDAQ: KOD) entered into a funding agreement with Baker Bros Advisors LP, wherein Baker Bros agreed to fund up to $225 million in exchange for the right to 4.5% royalties on Kodiak’s potential future net sales of KSI-301 and certain other products.

  • The royalty was capped at 4.5 times the total amount funded under the Funding Agreement.

  • By February 2020, Baker Bros funded $100 million, with the remaining $125 million to be provided after achieving specified criteria.

  • At Kodiak’s request, Baker Bros acknowledged and confirmed that the second funding amount would not be paid, and the aggregate royalty cap would be reduced from around $1 billion to $450 million.

  • The request was made in light of, among other factors, Kodiak’s strong balance sheet and its clinical trial progress.

  • As of March, the cash balance stood at 9 million.

  • Price Action: KOD shares are down 3.8% at $84.77 during the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.